IN PRESS: 52/1/2022

By |2022-02-10T07:40:30-08:00January 28th, 2022|Articles in Press, Brief Bulletins from the Field, We Know Psychiatry|

  ORIGINAL RESEARCH Doxepin for Insomnia: Executive Function before and after Treatment By Zhenghe YU, Li HAN, Pan YAN, Wenjuan LIU, Lishan REN, You XU, Lili YANG, Lisha MA, Youdan WEI, Yi LIU, Shengdong WANG DRUG DISPOSITION AND PHARMACOKINETICS Protein Biomarkers in Monocytes and CD4+ Lymphocytes for Predicting Lithium Treatment Response of [...]

Orally Dissolving Buprenorphine Tied to Severe Tooth Decay

By |2022-01-31T08:48:07-08:00January 17th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

Orally dissolving medications containing buprenorphine are linked to severe dental problems, including total tooth loss, the US Food and Drug Administration (FDA) warns in a safety communication. The oral side effects of these medications, which are used to treat opioid use disorder (OUD) and pain, include cavities/tooth decay, including rampant caries; dental abscesses/infection; tooth [...]

Aaron Beck, Father of Cognitive Behavioral Therapy, Dies at 100

By |2021-11-02T10:53:15-07:00November 2nd, 2021|Brief Bulletins from the Field, We Know Psychiatry|

Aaron "Tim" Beck, MD, known as the father of cognitive behavioral therapy (CBT), died on Monday in Philadelphia. He was 100. Beck's pioneering career in psychoanalysis spanned more than seven decades, yielding more than 600 published articles and nearly two dozen books. His development of CBT redefined the practice of [...]

Antidepressant May Cut COVID-Related Hospitalization, Mortality

By |2022-01-31T09:35:53-08:00October 28th, 2021|Brief Bulletins from the Field, We Know Psychiatry|

The antidepressant fluvoxamine (Luvox) may prevent hospitalization and death in outpatients with COVID-19, new research suggests. Results from the placebo-controlled, multisite, phase 3 TOGETHER trial showed that in COVID-19 outpatients at high risk for complications, hospitalizations were cut by 66% and deaths were reduced by 91% in those who tolerated fluvoxamine. "Our [...]

FDA Gives Nod for New High-Dose Naloxone for Opioid Overdose

By |2021-10-18T15:35:46-07:00October 18th, 2021|Brief Bulletins from the Field, We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved a high-dose naloxone injection product for the emergency treatment of opioid overdose. ZIMHI from Adamis Pharmaceuticals is administered using a single-dose, prefilled syringe that delivers 5 mg of naloxone hydrochloride solution through intramuscular or subcutaneous injection. Naloxone is an opioid antagonist [...]

Johnson & Johnson gets FDA nod for twice-yearly schizophrenia drug, Invega Hafyera

By |2021-11-11T16:56:29-08:00September 1st, 2021|Brief Bulletins from the Field, We Know Psychiatry|

Johnson & Johnson thinks a longer-acting treatment against schizophrenia will help keep patients on their prescriptions and reduce their chances of a relapse. Now, with a FDA nod under its belt, the company is pushing Invega Hafyera as just the med to fit the bill. The FDA Wednesday approved J&J’s [...]

Placebo-controlled trial: The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain

By |2021-08-23T10:20:11-07:00August 23rd, 2021|Brief Bulletins from the Field, We Know Psychiatry|

Background Precise cannabis treatment dosing remains a major challenge, leading to physicians’ reluctance to prescribe medical cannabis. Objective To test the pharmacokinetics, analgesic effect, cognitive performance and safety effects of an innovative medical device that enables the delivery of inhaled therapeutic doses of Δ9-Tetrahydrocannabinol (THC) in patients with chronic pain. [...]

Check List for Suicide Risk is Validated

By |2021-11-11T16:56:43-08:00August 16th, 2021|Brief Bulletins from the Field, We Know Psychiatry|

The objective of this research was to develop and evaluate an evidence-based suicide attempt risk checklist [i.e., the Durham Risk Score (DRS)] to aid clinicians in the identification of individuals at risk for attempting suicide in the future. Methods and findings Three prospective cohort studies, including a population-based study from [...]

Biogen Withdrew Aduhelm Paper After JAMA Asked for Edits

By |2021-08-03T09:26:20-07:00August 3rd, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

According to well-placed recent reports, Biogen Inc withdrew its paper that analyzed results from the clinical trials of its controversial Alzheimer's drug, Aduhelm, that was submitted to medical journal JAMA. Biogen withdrew the paper as JAMA considered rejecting it unless edits were made, according to the report. (https://bit.ly/3f2zsvf) The U.S. [...]

Go to Top